Related Experiment Video
Updated: Sep 21, 2025
05:56
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
9.0K
The Role of Atropine in Preventing Myopia Progression: An Update
Alberto Chierigo1,2, Lorenzo Ferro Desideri1,2, Carlo Enrico Traverso1,2
1IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, 16132 Genoa, Italy.
Pharmaceutics
|May 28, 2022
Summary
Low-concentration topical atropine effectively slows myopia progression in children. Further research is needed to determine optimal formulations and long-term treatment strategies for myopia control.
Area of Science:
- Ophthalmology
- Pediatric Medicine
- Pharmacology
Background:
- Myopia progression in children and teenagers is a growing concern.
- Topical atropine is increasingly used for myopia control, but optimal strategies are unclear.
Purpose of the Study:
- To review the evidence for topical atropine in myopia progression.
- To discuss pharmacokinetic, pharmacodynamic, clinical, and tolerability data.
- To identify gaps in current knowledge regarding optimal atropine use.
Main Methods:
- Review of multicenter, randomized trials including ATOM 1, ATOM 2, and the LAMP Study.
- Analysis of pharmacokinetic, pharmacodynamic, clinical efficacy, and tolerability data.
- Discussion of concentration-dependent effects and potential rebound phenomena.
Main Results:
- Low-concentration atropine (0.025%, 0.05%) demonstrates efficacy in slowing myopia progression.
- A concentration-dependent response was observed.
- These effective low-dose formulations are not yet standard clinical practice globally.
Conclusions:
- Low-concentration topical atropine is a promising treatment for pediatric myopia control.
- Further large-scale studies are required to establish optimal dosages and treatment regimens.
- Long-term efficacy, rebound effects, and stabilization potential need further investigation.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
619
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
619
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.4K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.4K
01:16Focusing of Light in the Eye
3.3K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
3.3K
01:28Angle Closure Glaucoma: Treatment
746
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
746
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.7K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.7K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
874
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
874